FDA declines to approve Satsuma’s migraine treatment STS101

19 Jan 2024
www.pharmaceutical-technology.com
NDAPhase 1AcquisitionClinical ResultPhase 3
FDA declines to approve Satsuma’s migraine treatment STS101
Preview
Source: Pharmaceutical Technology
STS101 is designed to be an easy-to-use and portable treatment option for migraine patients. Credit: Photoroyalty / Shutterstock.com.
The US Food and Drug Administration (FDA) has declined to approve Shin Nippon Biomedical Laboratories (SNBL) subsidiary Satsuma Pharmaceuticals’ investigational product STS101 (dihydroergotamine nasal powder) for acute migraine treatment in adults.
STS101 is designed to be an easy-to-use and portable treatment option for migraine patients, incorporating the company’s advanced powder formulation of dihydroergotamine delivered through a nasal device.
Satsuma submitted a new drug application (NDA) for STS101 to the FDA in March 2023.
The regulator issued a complete response letter to the company’s NDA, citing chemistry, manufacturing and controls issues as the primary reasons for its decision.
Satsuma has announced its intention to consult with the FDA to determine possible timing for a resubmission of the application.
The CRL did not raise any issues linked to the clinical data package submitted for STS101 or seek further clinical trials for the product’s approval.
The FDA based its NDA review of STS101 on the findings from two key clinical studies: a Phase I pharmacokinetic trial and the ASCEND Phase III open-label, long-term safety trial.
Data from these trials indicated that STS101 allows for quick absorption and attains high dihydroergotamine plasma concentrations and long-lasting plasma levels.
The asset also demonstrated safety and tolerability in individuals experiencing migraines.
Satsuma Pharmaceuticals president and CEO Dr Ryoichi Nagata stated: “We remain committed to working expeditiously with the FDA to complete the review for STS101 as soon as possible.”
SNBL subsequently signed a definitive agreement for the acquisition of Satsuma for $0.91 in cash per share plus a non-tradeable contingent value right (CVR) of up to $5.77 per share.
Based on the potential sale, licence or any other monetisation events linked to STS101, SNBL agreed to make the CVR payment.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.